Eli Lilly CEO: We're Pleased With Our 3Q Performance

The transcript covers a discussion on financial performance, product pipeline, and market expectations. It highlights the success of Trulicity in the diabetes market and the strategic importance of the Animal Health Unit. The speaker emphasizes the need for innovation in the pharmaceutical industry and advises policymakers on supporting drug development.

What challenges has the company faced in the past eight years?

What is the company's stance on the animal health business?

What advice does the CEO give regarding drug pricing pressures?